Xencor: Plamotamab NHL Data Leads To RA Program Advancement [Seeking Alpha]
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: Seeking Alpha
Terry Chrisomalis Investing Group Leader Follow Play 15min Summary Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of the phase 1b/2a study, using Plamotamab for the treatment of patients with multi-drug resistant Rheumatoid Arthritis, expected 1st half of 2025. XmAb657 is a long-acting CD19 X CD3 bispecific antibody being developed to target patients with autoimmune disorders; Phase 1 trial initiation for this program expected 2nd half of 2025. The global Rheumatoid Arthritis drugs market size is expected to reach $53.1 billion by 2031. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Black Friday Sale: Get 20% Off JTKPHOTOz/iStock via Getty Images The last time I wrote an article on Xencor, Inc. NASDAQ: XNC
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $34.00 price target on the stock, up previously from $32.00.MarketBeat
- Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $28.00. They now have an "overweight" rating on the stock.MarketBeat
- Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $38.00 price target on the stock.MarketBeat
XNCR
Earnings
- 11/6/24 - Beat
XNCR
Sec Filings
- 11/21/24 - Form 144
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- XNCR's page on the SEC website